TheraRadar
← Back
Data updated: Sep 20, 2026

SHILPA

Pharma

SHILPA is a pharmaceutical company focused on Oncology, Gastroenterology.

2015
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

SHILPA's Key Drugs

SHILPA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SHILPA's Recent FDA Approvals

New NDA/BLA approvals for SHILPA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SHILPA's Therapeutic Areas

SHILPA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 67%
2 drugs
Gastroenterology 33%
1 drugs

SHILPA's Top Competitors

SHILPA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SHILPA Pipeline Snapshot

Active clinical trials for SHILPA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling